title: AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION): 5-Year Update.
abstract: Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) is the first-ever international network created to design and conduct large-scale, multicenter clinical trials and research in persistently antiphospholipid antibody (aPL)-positive patients. Since its inception in 2010, the APS ACTION has made important strides toward our goal of international research collaboration and data sharing. Through the dedication and hard work of 50 APS ACTION members, collaborative international projects are currently underway including a multicenter web-based registry and repository of aPL-positive patients, a randomized controlled clinical trial assessing the efficacy of hydroxychloroquine for primary thrombosis prevention in persistently aPL-positive but thrombosis-free patients, standardization of aPL testing through the use of core laboratories worldwide, identification of the limitations in the existing aPL/APS literature, and conducting observational research studies to further our understanding of the disease. Thus far, APS ACTION has held annual workshops and summits with the aim of facilitating international collaboration and developing initiatives to recruit young scholars to APS research. This paper describes updates related to the organization's structure, ongoing research efforts, and recent accomplishments and discusses future directions.
authors.affiliation: Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
authors.forename: Medha
authors.initials: M
authors.lastname: Barbhaiya
authors.affiliation: University of São Paulo, São Paulo, Brazil.
authors.forename: Danieli
authors.initials: D
authors.lastname: Andrade
authors.affiliation: Barbara Volcker Center for Women and Rheumatic Diseases, Hospital for Special Surgery, 535 East 70th Street, New York, NY, 10021, USA. erkand@hss.edu.|Hospital for Special Surgery, New York, NY, USA. erkand@hss.edu.|Weill Cornell Medicine, New York, NY, USA. erkand@hss.edu.
authors.forename: Doruk
authors.initials: D
authors.lastname: Erkan
mesh_terms: D017152:Antibodies, Antiphospholipid / Q000276:immunology; D016736:Antiphospholipid Syndrome / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D006886:Hydroxychloroquine / Q000627:therapeutic use*; D013927:Thrombosis / Q000209:etiology / Q000276:immunology / Q000517:prevention & control*
chemical_list: D017152:Antibodies, Antiphospholipid; D018501:Antirheumatic Agents; D006886:Hydroxychloroquine
keywords: APS ACTION; Antiphospholipid antibodies; Antiphospholipid syndrome; Clinical trial